Form D · Biotechnology
Orbus Therapeutics, Inc.
Palo Alto, CA · CIK 0001650743
Offering snapshot reported Aug 11, 2020 · SEC filing
- Reported sold
- $10M Offering amount: $27M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 27, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 11, 2020 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Mar 20, 2019 | Amendment | $18,500,014 | $6,000,009vs Aug 15, 2017 | 16 | SEC filing |
| Aug 15, 2017 | Initial | $12,500,005 | No comparison | 16 | SEC filing |
| Aug 21, 2015 | Initial | $18,000,005 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-372998
Source: Form D, filed Aug 11, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Patrick Enright | Director |
| Elisha (Terry) Gould | Director |
| Jason D. Levin | Director, Executive |
| Ernest Mario | Director |
| Robert M. Myers | Director, Executive |
| Kurt Von Emster | Director |
| Michael Wasserman | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2479 East Bayshore Road
Palo Alto, CA, 94303
Palo Alto, CA, 94303